Search

Background: A micellar-HPLC method was developed for the determination of oxaliplatin (OHP) and curcumin (CUR) employing a C18 column [4.6 × 250 mm, particle size (dp)  = 5 µm] and diode array detector., Objective: A rapid, cost-effective, environmentally friendly, time-efficient, easy-to-handle, and safe method was developed., Methods: The conditions were optimized for the estimation of OHP and CUR: 0.15 M sodium dodecyl sulfate (SDS) in 6% (v/v) pentanol buffered to pH 5.0 with a flow rate of 1.0 mL/min, injection volume of 20 µL, and detection at 325 nm. Different analytical parameters, including linearity, accuracy, precision, robustness, specificity, LOD, and LOQ, were determined in compliance with the International Council on Harmonisation (ICH) guidelines., Results: The LOD (S/N = 3) of OHP was 0.004 µg/mL and for CUR it was 0.005 µg/mL. The calibration curves for OHP and CUR were linear over the range 0.015-10 µg/mL (determination coefficient r2 = 0.9999) and 0.015-10 µg/mL (r2 = 0.9994), respectively., Conclusion: The drugs were eluted in <12 min and the developed method was applicable for analyzing multiple samples per day. Moreover, it was determined to be robust and was used to quantify OHP and CUR in mice serum/blood. The method could pave the way for quantitative analysis of these drugs during the development of a pharmaceutical preparation for the treatment of colorectal cancer., Highlights: A simple, cost-effective, eco-friendly HPLC method was developed to simultaneously estimate oxaliplatin and curcumin. The developed method was validated as per the ICH guidelines., (© The Author(s) 2022. Published by Oxford University Press on behalf of AOAC INTERNATIONAL. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Cancer accounts for the second major cause of death globally. Conventional cancer therapies lead to systemic toxicity that forbids their long term application. Besides, tumor resistance and recurrence have been observed in the majority of cases. Thus, the development of such therapy, which will pose minimum side effects, is the need of the hour. Curcumin or diferuloylmethane (CUR) is a natural polyphenol bioactive (obtained from Curcuma longa) which possesses anti-cancer and chemo-preventive activity. It acts by modulating various components of signaling cascades that are involved in cancer cell proliferation, invasion, and apoptosis process. It interacts with the adaptive and innate immune systems of our body and causes tumor regression. This may be the reason behind the attainment of in vivo anti-tumor activity at a very low concentration. Its ease of availability, safety profile, low cost, and multifaceted role in cancer prevention and treatment has made it a promising agent for chemoprevention of many cancers. Regardless of the phenomenal properties, its clinical utility is haltered due to its low aqueous solubility, poor bioavailability, rapid metabolism, and low cellular uptake. In the last few years, a variety of novel drug carriers have been fabricated to enhance the bioavailability and pharmacokinetic profile of CUR to attain better targeting of cancer. In this review, the recent developments in the arena of nanoformulations, like liposomes, polymeric NPs, solid lipid NPs (SNPs), polymeric micelles, nanoemulsions, microspheres, nanogels, etc. in anticancer therapy have been discussed along with a brief overview of the molecular targets for CUR in cancer therapy and role of CUR in cancer immunotherapy., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Background: Curcumin has been extensively employed in the treatment of several diseases in traditional medicine, including cancer. The main obstacles that avert its approval as a therapeutic moiety are its low aqueous solubility and low in vivo bioavailability. Liposomes have been recognized as effective carrier systems owing to their ability to solubilize hydrophobic molecules and to change their pharmacokinetic attributes. This study was intended at developing Eudragit S 100 coated alginate beads bearing curcumin loaded liposomes for colonic delivery. Methods: The liposomes were prepared by the film casting method. The optimization of various formulation and process variables was done by Box-Behnken design using Design-Expert® Software. Three variables i.e.HSPC:Chol molar ratio (X1), curcumin concentration (X2), and sonication time (X3) were selected as independent variables and entrapment efficiency of curcumin, polydispersity index, and vesicle size were selected as dependent variables. Results: The optimized liposomes had an average particle size of 109. 8 ± 1.4 nm, polydispersity index 0.218 ± 1.2, zeta potential +19.30 ± 2.46 mV, and with entrapment efficiency 70.16 ± 1.6 %. These liposomes were entrapped in eudragit coated beads and these beads were characterized for their size, swelling index and in vitro drug release. The in vitro drug release depicted that no release was observed till 6 hrs and a sustained and significant drug release was noted after 6.5 hr. Conclusion: The stability studies indicated that liposomes were stable at 4°C depicting little aggregation of the vesicles. The research suggested that curcumin-loaded liposomes bearing eudragit coated calcium alginate beads can be effectively used for colonic delivery. [ABSTRACT FROM AUTHOR]